That’s because it’s gradually dawning on investors that they no longer can count on lower interest rates and inflation to support higher stock and bond prices. They are realizing that ...

Our mission is to support the development of Clinical Psychology, both as a profession and as a body of knowledge and skills. By working collaboratively with a number of organisations including the ...

The Northern Ireland Clinical Academic Training Programme at Queen’s, offers opportunities at different levels to experience high quality research and prepare for a future career in research and ...

Decided to add this retail giant to your portfolio? Here's what you need to know before buying Amazon stock. Many, or all, of the products featured on this page are from our advertising partners ...

However, one stock bucked the broader market trend—Wockhardt Ltd., a pharmaceutical sector player, which saw its share price climb by 1.28 per cent. Wockhardt Ltd. has been a remarkable performer over ...

Stock market crash: Indian stocks came under significant selling pressure in Friday's trading session, January 17, driven by a sharp sell-off in banking and IT counters, which caused the frontline ...

Anonymous image hosting can be important when wanting to upload content that might be sensitive or controversial, especially if you're a journalist or a whistleblower looking to expose something ...

The company's innovative approach to gene editing has garnered significant attention from investors and analysts alike, with its stock performance closely tied to upcoming clinical milestones and ...

Neumora Therapeutics Inc.’s stock tumbled 81% Thursday after the clinical-stage biotech said a late-stage trial of a treatment for major depressive disorder failed to meet its main goals.

The company's innovative approach to gene editing has garnered significant attention from investors and analysts alike, with its stock performance closely tied to upcoming clinical milestones and the ...

Clinical data for AlphaVac and NanoKnife were ... but management indicated that the study hit all primary endpoints, with 84% of patients free of in-field clinically significant disease at 12 ...